Dublin, Dec. 07, 2023 (GLOBE NEWSWIRE) -- The "Crohn's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.
This report covers key aspects such as disease management, epidemiology, pipeline assessment, unmet needs, and drug forecasts running through to the year 2032. The detailed analysis focuses on the eight major markets (8MM), including the US, France, Germany, Italy, Spain, UK, Japan, and Canada, providing a robust Excel-based forecast model for stakeholders to analyze.
According to the report, the CD market across the 8MM is on the cusp of considerable expansion, projected to grow from 9.5 billion USD to an impressive 15 billion USD by 2032, marking a compound annual growth rate (CAGR) of 4.7%.
A notable surge in this market segment is anticipated, catalyzed by the approval and launch of 15 predicted pipeline entities, including generic and biosimilar treatments.
Significant growth drivers within the CD therapeutics landscape have been identified as the advent of novel and advanced therapies that demonstrably enhance therapeutic efficacy, favorable legal outcomes supporting pharmaceutical drug pricing, and updated rapid integration protocols for new therapies by healthcare systems.
- Understanding of the evolving epidemiological patterns of CD
- In-depth review of current treatment paradigms
- Analysis of the competitive landscape with a spotlight on market leaders and emerging companies
- Strategic intelligence on driving factors and potential market growth obstacles
- Comprehensive pipeline analysis spotlighting cutting-edge treatments on the horizon
The analysis presents valuable market intelligence critical for designing strategic business moves, capturing insights on market evolution, and envisaging scenarios for revenue growth. Stakeholders are equipped to frame potent sales and marketing strategies while staying abreast with the competitive milieu and identifying the segments ripe for investment and synergistic alliances.
Ultimately, this report promises to be an indispensable resource for companies seeking to understand the trajectory of the CD market. It provides an aerial view of the drug sales within the CD therapeutics space and is instrumental for coordinating market efforts to tap into the segments presenting the most significant potentials for growth and consolidation.
Highlighting Key Market Drivers and Barriers in CD Therapeutics
As CD continues to pose clinical challenges worldwide, understanding the market dynamics, including drivers and barriers, remains crucial. This publication unravels the complexities of the CD market, presenting a granular analysis that affords stakeholders a competitive edge and a foresight-filled perspective into the next decade.
In conclusion, the latest research pivots on a wealth of data and forecasts, setting the stage for transformative strategies in disease management and therapeutic advancements in Crohn's Disease across the 8MM. It paves the way for impactful decisions that could shape the future of CD treatment and the well-being of those affected by this chronic condition.
The report features the following companies:
- AbbVie
- Bristol Myers Squibb
- Janssen
- Lilly
- Merck
- Pfizer
- Takeda
- Telavant
- Teva Pharmaceuticals
- Ventyx Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/hv1emy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
